Synaptogenix, Inc. (NASDAQ:SNPX – Get Free Report) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 11,300 shares, a growth of 130.6% from the August 31st total of 4,900 shares. Based on an average daily volume of 37,300 shares, the short-interest ratio is currently 0.3 days. Approximately 0.9% of the company’s stock are short sold.
Synaptogenix Trading Down 5.4 %
Shares of SNPX stock traded down $0.17 during trading hours on Friday, hitting $2.97. The company had a trading volume of 8,864 shares, compared to its average volume of 39,917. The firm’s fifty day moving average is $3.59 and its 200 day moving average is $4.21. Synaptogenix has a 12 month low of $2.72 and a 12 month high of $11.47.
Synaptogenix (NASDAQ:SNPX – Get Free Report) last announced its earnings results on Wednesday, August 14th. The company reported ($1.18) earnings per share for the quarter.
Wall Street Analysts Forecast Growth
View Our Latest Analysis on SNPX
Synaptogenix Company Profile
Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.
See Also
- Five stocks we like better than Synaptogenix
- Using the MarketBeat Dividend Yield Calculator
- CarMax’s Impressive Rally: What Investors Should Watch Next
- Upcoming IPO Stock Lockup Period, Explained
- MarketBeat Week in Review – 9/23 – 9/27
- What is the FTSE 100 index?
- Wake Up to This Biotech Stock That Still Has Big Potential Upside
Receive News & Ratings for Synaptogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synaptogenix and related companies with MarketBeat.com's FREE daily email newsletter.